TIGAR (chromosome 12 open reading frame 5) by Simon Molas, Helga et al.
11/4/2016 TIGAR (chromosome 12 open reading frame 5) 
Atlas of Genetics and Cytogenetics in Oncology and Haematology 
Horre Genes Leukemias Solid Turnours Cancer-Prone Deep fusight Case Rtmorts Journals Portal Teaching 
TIGAR ( chromosome 12 open reading frame 5) 
Written 2013-12 Helga Simon, Ana Rodríguez-García, Áurea Navarro-Sabaté, Pere Fontova, Ramon Bartrons, Anna Manzano 
Departa~mnt de Ciencies Fisiologiques II, Campus de Bellvitge, Universitat de Barcelona, Feb<a Uarga s/n, 08907, I:Hospitalet de 
Llobregat, Barcelona, Spain 





















Starts at 4430359 and ends at 4469190 bp frompter ( accordingto hg19-Feb_2009) 
TIGAR (12p13.32) / TIGAR (12p13.32) TIGAR (12p13.32) 1 TSP AN9 (12p 13.33) 
4424533 
1 Chr01110$0IIW 12NC_0001'2.11 
4475013 
c12ort5 
(4424533 .. 35901 - :!:601 1 (4475018 .. 
~~--~----+---~--------~~ .. ----~r --saz7- 5937 15914 - 15951 2·1673- 21794 34453 - 34530 38894- 4461lo2 50486 Géne Séqvénee 
mRNANM_02037S.2 
8237 mRNA aeqU&nca 
Figure l. Schematic representation ofTIGAR location in chromosome 12, gene structure and transcript mRNA. Different numbering has been used 
considering chromosomal, gene or mRNA sequence . 
The human TIGAR gene i<; composed of6 exons spanning genomic region about 50,4 kb (GenBank: NC 000012.11 ). The transcript 
mRNA i<; 8,2 kb (GenBank NM 020375.2) and it is composed by the exonregions 5827 .. 5937, 15914 .. 15951, 21673 .. 21 794, 
34453 .. 34530, 35901 .. 36011 and 36894 .. 44662. 
The human TIGAR coding sequence consÍ<lts of813 bp from the start codon to the stop codon There are no splicingvariants reported. 
A pseudo gene of the ribo soma! protein S 15 has been located in the region 8981.. 94 73 by computational analysis using a gene prediction 
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Figure 2. DiagramofTIGAR structure from PDB (entry number: 3DCY). The PDF file do es not contain inforrnation about the parts ofthe sequence that are 
not underlined. 
Human TIGAR protein consists of270 arninoacids, with a molecular weight of30063 Da. It is cornposed of a bisphosphatase active site 
in which two histidines, His-11 and His-198, and one glutamic acid, Glu-1 02, are key residues fur its fimctiorL TIGAR catalytic domain 
belongs to the histidine phosphatase superfumily of proteins, a conserved group of proteins which contain a domain with a histidine forming 
a phosphoenzyme transiently during the catalysis (Rigden, 2008). This domain shares similarity with enzymes ofthe phosphoglycerate 
rrutase fumily (PGAM) and with the bisphosphatase domain of6-phosphofructo-2-kinase/:6:uctose-2,6-bisphosphatase (PFK-2/FBPase-
2.), in which the three aminoacids in the catalytic domain are conserved. 
More infurmation about TIGAR protein can be fuund in Uniprot 0 9N088. 
Human TIGAR structure contains different motilS as represented in the image below (PDB reference 3DCY). 
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Figure 3. Human TIGAR crystalized structure visualization in Jirol software. His-11 is represented in white, Glu-102 is in purple, His-198 is colored green and 
C and N terminus are represented in red and blue, respectively. A) General protein view. B) Zoomofthe visualization to the catalytic core, with the two 
histidines represented and the phosphate group painted following the consensus-based coloring ofatoms. C) Protein surface and ins ide-core 
representation. The central core ofthe protein is corqJOsed by a six-stranded mixed ~ sheet flanked hy a he !ices on both sides. 
TIGAR rnRNA is expressed in all the tissues in wbich it has been analysed and it is overexpressed in severa! cancer celllines such as T-
lymph Jurkat cancer, kidney HEK.-293, liver HuH-7 and HepG2, hmg A549, colon RKO, bone U20S, brain GAMG, prostate LnCap, 
cervix He La and breast MCF7. 
All this infurmation can be fuund in GeneCards ( sections proteins and expression). 
TIGAR is mainly localized in the cytoplasm Under hypoxic conditions, a relocalization ofthe protein linked to HK-2 (hexokinase 2) in the 
outer mitochondrial rrembrane has been described (Mathupala et al, 2009; Cheung et al, 2012). 
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Figure 4. Schematic n:pn:sentation ofTIGAR in metabolic pathways. The DBin enzymes involved in glycolysis are shown, as well as the substmtes and 
produclll ofTIGARactivity. The pentose phosphate pathway and mitochondrial metabolic pathways have been s1IIIDII1i2l:d. HK: heJDkinase, PGl: 
phosphoglucosc isoJDCtase, PFKFB3: phosphoftucto-2-kinaselftuctose-2,~il!lphosphatase 3, PFK.-1: phosphoftuctokinase-1, DHAP: dihydro~acetone 
phosphate, GA-3-P: glycemldehyde 3-phosphatc, GAPDH: glyceraldehyde 3-phosphate dehydrogenase, 1,3-BPG: 1,3-bisphosphoglyccrate, mTORCl: 
!TJU!"IIJl]jan target ofmpamycin co~q~lcx 1, PFP: phoshoenolpyruvate, <EH: gllltathione. 
TIGAR was identified by microarray amlysis of gene mcpressim a1ler TP53 ioduction (Bensaad et al, 2006). TIGAR plays a role in the 
11'53 tunm suppressor program by reducing reactive oxygen specils (ROS) levels and prevenling DNA datmge-ioduced apoptosi!. 
Their fimctions are based on glyoolysis :inbibilion and tbe enbancemmt ofpentose phosphate pa1hway (PPP). 
TIGAR is a bisphosphatase tbat hydrol;yB:s Fructose-2,6-bisphosphate to Fructose-6-phosphate, whi:h can elller tbe PPP to genemte 
NADPH and ribose-5-phosphate, tbus, redix;iog oxilative stress and genemtiog mx:leotile pn:cursors (Bensaad et al, 2006). 
Beta-D-ftuctose 2,6-bisphosphate + H20 ~ D-ftuctose 6-phospbate + phospbate 
The switch ftmn 11'53-ioduced cell-cycle arrest to apoptosi! futbwiog mainmined stress is associated wilh downregulati>n ofTIGAR and 
therefure 1he loss ofP53-depemem surviwl agents coukl be the cause oftbe apoptoti: response. It has been proposed that TP53-
depemem m:tabolism regulation coukl be orcll:strated by dili:reDt m:cbanismi other than 1he ones that regulare TP53-ioduced 
apoptosil. TIGAR antiapoptoti: efli:cts are oxilative-stress depe.ndent. The apoptosis ioducti>n by other m:chanimJ; i; mt affi:ctcd by 
TIGAR, as i1 was shown in .IL:.l-dependent. apoptosis FL5.12 cel linc, and in a.nti-Fas ioduced apoptosis in U20S cels, suggestiog tbat 
TIGAR can m>dulate apoptosis in a ce1l-depemem manner {Bensaad et al., 2006). 
As descrbed prevhusly, under hypoxi: conditi>ns TIGAR is localillld in outer mitocbondrial meni>rane. In 1hW situati>n, it biods together 
wilh HK2 to mitochondria (Mathupala et al., 2009) in a HIF1a (hypoxia-induchle mctor la) dependent manner, and limits ROS levels. If 
HK2 is not present, oxidative stress reducti>n by TIGAR is lower. It has been shown tbat mutant TIGAR 1M (Triple Mutant wi1hout 
enzyiiBti: activi1y: HllA/El 02A/Hl98A) is able to relocaJm: to mlochomria in response to hypoxia alll. iDdeed, is able to biod to HK2 
in the outer mitochomrial m:mbranc. Thcrefure, tbe maiorenance of mitochomrialmeni>rane potential by TIGAR il iodepemem ofits 
bisphoshatase activity. Howcver, the siogle deleti>n offuur amiooacids in the C-teiminus (258-261) awided TIGAR m>bilizati>n to the 
mitochondria a1ler hypoxia, altlxlugh its bisphosphatase activity remained umlt.ered. The double mutant 1M TIGAR/258-261 was notable 
to l"edooe ROS lewls {Bensaad et al., 2006; Cheurlg et al, 2012). In cooolusion, TIGAR hwers ROS levels both by :inbibiting glycolysti 
and by eDhancing an adequate mitocbomrial fuooti>n coupling to HK2. 
TIGAR efrects ha ve üo been related to autophagy as an inhibilion ofthis cen process was described wben cells were exposed to stress 
condiliotJ¡ such as IllllrieDt starvati>n or m:tabolic stress, in parailel wilh an overexpression ofTIGAR and a decrease in ROS cellewls. 
After TIGAR suppression, autophagywas ioduced to mxlerate apoptoti: response by restrainiog ROS lcvels {Bensaad et al, 2009). 
The relati>n between autophagy and apoptosi! can be m>dulated diOi:rently depemling on tbe stilwlus and cel type. D-galactose (D-ga]) 
trea1m:Dt ofncuroblastoiiB cels induced nocroptosis and autophagy, as shown by upregulati>n ofBmt; lkli!l, ~ and TIGAR, but 
there were no changes inmcpression in genes related to apoptosti (Liet al., 2011). 
Recently, it has been described a decrease in steady-state mRNA levels ofTIGAR when dJe lnmm bepatoce1kmr carcinoma HepG2 cen 
b was exposed to bigh oxilative stress conditi>ns ioduced by 1he superoxide radi:al-genemting m:nadione, hydrogen peroxide (H:P:z) 
or IllllrieDt starwtion, in para.llel wilh a down-regulati>n ofthe dalmge-regulated autophagymxlulator (DRAM). mRN A levels ofboth 
genes were recovered when ceJlci were treated wilh anl.ioxXiants such as GSH or N -acetyk:ysteine, suggestiog a corrplex regulati>n of 
tumor suppressor gemlS by ROS levels (K.im.et al., 2013). In front ofa disruption in the hom:ostasis balance oftbe cen, TIGAR woukl 
provide cytoprotecti>n by its anlioxidant propertils rather tban its ability to inhibit autophagy. After a tbreateniog stimulus, a rapü ia::rease 
in the autophagi; 1lux occum m>stly regulated by post-translat:ional m>difications, fullowed by a transcriptiomlly-m:diated delayed 
autophagyc response phase, in whi:h TP53 woukl be actiwted. In this conn:xt, TIGAR woukl be rapilly transactiwted and woukl 
m:diate its antiJxidant response, wbile autophagy ti enha.nced by other transcr.ptionally activated targets, such as DRAM (Pietrocola et 
al, 2013). Som:: 8l.thors have proposed a TP53-orchcstrated m:cbanism bywhi:h this protein woukl regulate stress-induced autophagy 
by balancing two proteins with opposite efli:cts: TIGAR and DRAM (Dewaele et al, 201 O; Zbang et al., 2010). 
In 11'53 knock-out mice (TP53-/-) cardnprotecti>n agaimt iscll:mic iqjury and resistance to cardiac rem>deliog were observed, anda 
significant TIGAR overexpression was described. The TIGAR kmck-out (TIGAR-1") had 1he sam: efli:cts anda TP53-depemem 
m:chauiml of autophagy :inbibilion tbrough tbe mitophagy enbm;;er Bnip3 was described. Double knock-out ofTP53 and TIGAR mice 
eJ!POsed to iscbemia responded with an iocrease in ROS lcvels, fullowed by an ovcrexpression ofBnip3 that lead to mitophagy alll. tl:nB, 
cardioprotecti>n. The activation of~3 and mitophagy was recovcred by NAC, confirming that TIGAR-m:diated mitophagy i:iliibition 
is m::diated by ROS. VeDiri;ular rem>deling a1ler myocantial infim:tion is a consequence ofboth iupajred mitocbondrial iolcgrity and 
enbanced apoptosis, whereas mitophagy belps ceJlci to undergo mitochomrial datmge and avo:id apoptosis, resulling in a dimioished initia1 
inlilrct size, less vetltOOular remxl.eling and restored homeostasis in iscll:mic myocardiwn (Kirmta et al, 2010; Hoshioo et al., 2012). 
The analysil ofhmg tissues ftom.:idiopatbK: puhnonaty fibrosis patients revealed decreased autophagyc activity, ev:id=d by less I.C3 and 
~ expression. When tbese cells were treated wilh TGFP in vilro, impairment in autophagywas observed, in parailel with an D:rease in 
TIGAR mcpression, ahhougb. the posshle m:chauiml connectiog TGF~ and TIGAR was not described (Pate1 et al., 20 12). 
In a co-cullure system, Martioc2l-Outschoom et al. showed that oxilative stress-ioduced autophagy correlated with ~ downregulati>n 
in caa:er associated fibroblasts, and with overexpression ofTIGAR in adjacent caa:er cells. Consequently, autophagy cancer associated 
fibroblasts provide recycled nutrients :fOr cancer cel m:taboliml alll. JilOreover, prevent cancer cels death byupregulatiog TIGAR and 
tbus con1erring resistance to apoptosis and autopbagy {Ma.rtineuOulschoorn et al., 201 0). Further studies by tbe sam: group 
dem>nstrated that tbe m:tabolic coupling between cancer ceJlci and fibroblasts can mcplain tam>xifim resistance as cancer associated 
fibroblasts enha.nce the activity ofTIGAR in cancer ceJlci, providing protecti>n against tam>xifim-ioduced apoptosil, whi:h was much 
bigber in m>nocullures of cancer cells alone (Mart:ine7,-0utschoom et al., 2011 ). In another study, glutamine was described as a needed 
fil.ctor fur Cav-1 downregulation in cancer associated fibroblasts and fur the decrease in autophagy mediators and markers in cancer cells, 
establisbi!lg a m>del in whi:h autophagy fibroblasts IIBY serve as a source of glutamine to fuel cancer cen mitocbondrial activity. Thcrefure, 
a cycle between catabolic tmnor stroma cels and anabolic tmnor ceJlci has been proposed to explain the relati>ns between cells in tmnor 
enviromnmt (K.o et al., 2011 ). 
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would probably increase cell death (Dodson et al, 2013). 
All these studies corúirm that TIGAR functions are not only restricted to glycolysis regulation, as this protein plays key roles in diffurent cell 
processes involving oxidative stress restriction 
Activation and regulation 
TIGAR belongs to that group ofTP53 target genes that beco me rapidly activated by low levels of stress. There are two possible TP53 
binding sites in TIGAR gene: one upstrearn ofthe first exon (BS 1) and one within the 1st intron (BS2), wbich is the llX)St efficient one and 
has been validated by chrornatin irrnnunoprecipitation (ChiP) analysi<; (Bensaad et al, 2006). 
In an experilrental approach, TIGAR was induced by Actinomycin D and Adriamycin (Bensaad et al, 2006), two well-known activators 
ofTP53, and also by Nutlin-3a, an antagoni<lt ofMdrn2 (Hasegawa et al, 2009). Other stimuli that have been described to trigger 
TIGAR expression are radiotherapy (Peña-Rico et al, 2011), glutamine (Ko et al, 2011), chellX)therapy (Madanet al, 2012), UV light 
(Madan et al, 2012), lNFa and radiotherapymimetics (Sinha et al, 2013). 
When DNA darnage occurs, TP53 is expressed either to repair DNA or lead the cell towards apoptosis. High ROS levels can 
compromise DNA stability wbich, in turn, could help cells to accUirulate mutations and become tmnorigenic. As TIGAR reduces ROS 
levels, it has been proposed as a turror suppressor gene, although it should be taken into account that, as TIGAR can help tmnor cells 
surviva~ it could actas an oncogene in sorne situations. TP53 is able to suppress tumor developrnent when rnechanisrns of apoptosis, 
senescence and cell-cycle arrestare impeded. This supports the idea that metabolism, and thereby TIGAR, has a key role in cancer 
development (Li et al, 2012; Valente et al, 2013). 
TIGAR expression can also be llX)dulated in a TP53 independent rnanner, as resuhs from studies with the TP53 null T98G and H1299 
celllines suggest (Bensaad et al, 2006; Peña-Rico et al, 2011 ). 1be mechanisrns implicated in the regulation ofTIGAR express:ion in the 
absence ofTP53 are unclear. The CRE-binding protein (CREB) has been described to regulate TIGAR express:ion through a CRE-
binding site at the TIGAR prollX)ter, whlch was first annotated by b:ioinfurrnatic analysis and then confirmed by electrophoretic llX)bility 
shift assay (EMSA) and ChiP. CREB knockdown reduced enbanced prollX)ter activity and TIGAR expression; whereas CREB 
overexpression resuhed in enhanced prollX)ter activity and TIGAR expression levels (Zou et al, 2013 ). Another transcription :filctor, SP 1, 
was fuund to bind to TIGAR prollX)ter in a SP1-binding site located in a very short region (-56/-4) both in vitro and in vivo, and was 
considered a key :filctor fur proper basal activity ofTIGAR prollX)ter (Zou et al, 20 12). Recently, sorne authors have identified HlF -1 a 
as a potential regulator ofSC02 and TIGAR gene expression suggesting the involvernent ofP300/CBP-associated :filctor (PCAF) in 
diffurential recruitment ofHIF -1 a and p53 to the prollX)ter ofTIGAR and/or SC02 genes in response ofhypoxia in tmnoral ce lis 
(Rajendran et al, 2013). 
Chromosomal rearrangements: copy number variants 
Sorne aherations affucting TIGAR genorne region have been described in patients, sorne ofthem showed phenotypic effucts. Gain of 
12:189578-34178209 resuhed in hydronephrosis, rnicrognathia, edema, depressed nasal bridge, tricuspid regurgitation and diaphragrnatic 
eventration Patients withgain of12:189561-41878937 suffured globaldevelopmentaldelay. The ones with gain of12:230361-
20643 702 showed intellectual disability and electroencephalogram with localized low amplitude activity, whereas gain of12 :191619-
8327369 resuhed in rnacroencephaly, visual impairment, intellectual disability, nmscular hipotonia, and seizures. 
For llX)re infurrnation, see DECIPHER 
Location in the llX)USe: chrollX)sorne 6, 61.92 cM, 127085116-127109550 bp, complernent strand (Mili). 
For a comparison ofthe gene allX)ng HollX) sapiens, llX)USe, rat, chirq>anzee, cattle, rhesus rnacaque, dog, chicken and zebrafish see 
MGI. 
F or all species known gene tree, see: Tree:film database. 
Specie Gene Query cover E value ldentity 
Pan troglodytes BAC clone CH251-597E5 32% 0.0 93% 
Pongo abelii BAC clone CH276-457P6 27% 0.0 94% 
Goliilla gmilla BAC clone CH277-2~ 1C13 26% 0.0 93% 
N. leucogenys CH271-261A22 28% 0.0 93% 
Mus musculus RIKEN librnry, F630005B03 5% 0.0 93% 
Gallusgallus Ribosomal protein s~s 0% 6e-·t23 86% 
Danio re~io Ribosomal protein S15 0% 2e-80 80% 
Figure 5. Orthologs (adapted fromBIAST Local Alignment Too!). 
There have been observed 22 sornatic mutations in patient turror samples collected in the COSMIC database. 
Nonsense substitutions: 1, located in c.466G>T (p.G156*). 
Missense substitutions: 16, whlch represent 82% of the mutations described allX)ng all patients. Only two missense substitutions ha ve been 
fuund in more than one patient: c.268A>G (p.R90G) was fuund in 5 patients and c.215G>T (p.R721) was fuund in 2 patients. 
Synon~us substitut:ions: 4. 
No deletions, insert:ions or chro11X)soma1 fus:ions in TIGAR gene have been described in any tmnor sample. 
Genomic variants 
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Figure 6. HistogramofDIItations found ammg the aminoacid sequence ofTIGARprotein. The maxim.Jmnumber ofsubstitutions at any specific genomic 
region is represented in Y axis. R90Gis the most comron aminoacid substitution, caused by 5 different genomic nrutations. Histidine phosphatase family 
homolog domain is represented in green and copy numbervariants are represented in blue (gain offunction) and red (loss offunction). Adapted from 
COSMIC Databas e. 
Various cancers 
Despite that little is known about the implication ofTIGAR in cancer, there are sorne authors that point out about the importance ofp53 
targets such as cytochrmre e oxidase 2 (SC02) or TIGAR in the prognosis ofbreast cancer patients. Sorne studies indicated that p53, 
the most connnonly nrutated tumor suppressor gene, rnay bave Ífi1lortant fimctions in the regulation of energy-generating metabolic 
pathways that switch from oxidative phosphorylation to glycolysis via the synthesis ofSC02 and TIGAR (Won et al, 2012). 
The p53 tumor suppressor pathway coordinates DNA repair, cell-cycle arrest, apoptosis, and senescence to preserve genomic stability 
and prevent tumor furmation. TIGAR bas been identified as a p53-inducible gene. TIGAR expression lowers fructose-2,6-bisphospbate 
levels in ce lis, resuhing in an inhibition of glycolysis and an overall decrease in ROS levels. These fimctions ofTIGAR corre late with an 
ability to protect ce lis from ROS-associated apoptosis, and consequently, knockdown of endogenous TIGAR expression sensitizes cells 
to p53-induced death. Expression ofTIGAR rnay therefore modulate the apoptotic response to p53, allowing survival in the fuce ofmild 
or transient stress signals that rnay be reversed or repaired. The decrease ofintracellular ROS levels in response to TIGAR rnay also play 
a role in the ability of p53 to protect from the acctnrulation of genomic darnage (Bensaad et al, 2006). In an in vitro model of 
nasopbaryngeal cancer, 1-(3-C-ethynyl-beta-d-ribo-pentofuranosyl) cytosine (ECyd), a RNA-nucleoside anti-rnetabolite with potent 
anticancer activity, acts by downregulating TIGAR and depleting NADPH. The overexpression ofTIGAR was able to rescue cells from 
ECyd-induced growth inhibition, demonstrating a novel rnecbanistic action ofECyd on TIGAR This study suggests a novel link between 
RN A rnetabolism and TIGAR regulation (Lui et al, 201 0). In human cervical carcinoma ce lis, RN Ai-mediated citrate synthase 
knockdown accelerated cancer cell rnetastasis and prolifuration being these effects related to deregulation ofthe p53ffiGAR and SC02 
pathways (Lin et al, 2012). In other studies, TIGAR also rnediates de-phosphorylation ofR!3 (retinoblastorna) and stabilisation ofRB-
E2F 1 complex thus delaying the entry of ce lis in S pbase ofthe ceO cycle. Thus, TIGAR inhlbits prolifuration of cancer cells and increases 
drug-rnediated tumour regression by promoting p53-rnediated cell-cycle arrest (Madan et al, 2011; Madan et al, 20 12). 
Hepatic cancer 
Silencing TIGAR by RNAi induces apoptotic and autopbagy cell death in HepG2 cells, and this data raise hope fur the future successful 
application ofTIGAR siRNA in patients with hepatocellular carcinoma (HCC) (Y e et al, 2013). 
Breast cancer 
In a model ofMCF7 breast cancer cells co-cultured with non-transfurrned fibroblasts, ghrtamine protects MCF7 cells against apoptosis, 
via the upregulation ofthe anti-apoptotic and anti-autopbagic protein TIGAR (Martinez-Outschoom et al, 2011). The authors showed 
that ghrtamine cooperates with strornal fibroblasts to confer tamoxifun-resistance in MCF7 cancer ce lis (K o et al, 2011 ). Moreover, Won 
et al (2012) bave analysed the expression ofp53, SC02, TIGAR, and COX in 113 cases ofinvasive breast cancer using 
immunohistochemistry. A highexpressionofp53, SC02, TIGAR, and COX was noted in 27,5% (31 cases), 84,1% (95 cases), 74,3% 
(84 cases), and 73,4% (83 cases) ofthe breast tumors, respectively. A high p53 expression was significantly associated with low 
expression levels ofSC02 (P = .008), COX (P < .0001), and TIGAR (P = .007). These resuhs suggest that p53 can modulate the 
rnetabolic pathways via the proteins SC02 and TIGAR in human breast cancer. TIGAR and p53 can lower the ceDular sensitivity to 
RO S-associated apoptosis, and this potentially contributes to the survival of ce lis undergoing mild, reversible stress by diffurent anti-
tumoral drugs (Won et al, 2012). 
Head and neck cancer 
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downregukmn ofTIGAR and subsequent deplemn ofiolracellular NADPH. The resuhs provne the first evKlence linking c-Met, TIGAR 
and NADPH regulamn in hmnan caiJ:er ceDs suggesti:lg that illhibitim of a tyrosine kinase!TIGARINADPH cascade may have 
tberapeuti: applicability in hmnan cancers (Lui et al, 2011 ). 
Lm!gcancer 
Sinthupibulyakit et al (2010) have shown that a glyoolyti: illhibitor, 2-deoxy-D-glucose (200), exbibits a cytoto:D: efli:ct on non-small 
cel hmg cancer in a p53-dependent manner. 200 signi&:antly illhibils A'IP producmn in p53-deticient hmg cancer ce& {H358) but not in 
p53-wt ce& (A549). This e1rect il explained by 1he ROS iocrease ftom OXPHOS tbat induces tbe expression of p53 anti>mams targets 
such as cytocbrome e oDiase 2 (SC02) and TIGAR. 'Thciefure, killiDg of cancer cells by thil illhibitor of glyoolysE is n:me ef&:icnt in 
cancer cells wihnl1 fimctDnal p53 tbat protects agail:m metabolic stress by up-regulation ofTIGAR (Sinthupbulyakit et al, 201 0). 
Other authors point out tbe irqx>rtance of autopbagy as a cellular homeostati: process to determine cel mte decilions uoder condili>ns of 
stress. Deregulamn of autopbagy irq¡acts numerous hmnan diseases includiDg cancer and cbroni: hmg dileases. TIGAR could be 
irq¡licated in the irq¡airment of autopbagy by TGF-~1) and mayrepresent a mecbanism fbr 1he prom>tion offibrogenesis in idDpathi: 
pulrnonaiy fibrosil (Pate1 et al, 20 12). 
Intestinal gm;er 111M1 ukenative ooliüs 
The ability ofTIGAR to cODtribute to 1he growth and survival of cells in rapDly prolifi:mtiog ti;sue suggested a possible contrbutVn of 
TIGAR to the devehpment or progressi>n ofmatignances. 1n a m>U'ie m>del ofintestinal tum>r illduced by deleti>n of Me. in tbe 
intestinal stem cels, TIGAR expression was increased anda reduction in turror development and an enbancement of survival in TIGAR-/-
mice were described. Furt:berm>re, usirlg an in vitro organoid cuhure :rrode~ irq¡aired growth ofTIGAR-/- cells derived from 1he crypt of 
the smal intestine was rescued by supplememati>n wih llliCieosides and the anti>xidanl: N -acetyl cysteine 1n 1he otber band, in a m>me 
m>de1 ofuk:erat:ive colilii TIGAR plays an ilqx>rtant role in tissue regenemti>n and that lack ofTIGAR resuhs in a "lililure to repair 
damagcd intestinal epihe!iJm. TIGAR is overex¡m:ssed in crypts during the recovery ofprolifi:ration in WT mice. The lack ofTIGAR 
resuhs in a fililure to repair damagcd intestinal epihelilm and increase in oxidative damage. 1n tbese systerm, thcreñre, TIGAR expression 
is necessary to maintain normal bea.llhy tissues fullowirlg stress or damage. Thcreñre, whilc hss ofTIGAR is delcterDus to the recovery 
from intestinal damage, lack ofTIGAR becomes advantageoU'i uoder condili>ns where enhanced prolifi:rati>n occurs in 1he context of 
tum>r devehpment and progression ofmatignarx:es. 1n conclusDn, TIGAR is not required fbr normal tissue growth and development but 
becomes irqlortant in supporting rapid prolifi:rati>n in adult intestinal epilhelium (Cheung et al, 20 13). 
Muhi,ple rqyeloua 
Mulq,le myeloma ceDs present problemi in the expression of oncoprotein MUC1-C. The inhbition ofMUC 1-C increases ROS and is 
also associated with down-regulation ofTIGAR, resulting in tbe decrease in NADPH and glutathione (GSH) leve ti. "1'00 suppression of 
TIGARand NADPH lcveti contributes to ROS-Jrediated apoptosis/necrosis ofmultiple myehma cells. These 1ind.ing9 indi::ate tbat 
nmltiple myehma cells are dependent on MUC1-C and TIGAR fbr maintenance ofredox balance and that targeting MUC 1-C activates a 
cascade inwlving TIGAR suppressi>n tbat conttibutes to multiple myehma ce U death (Yin et al, 20 12). 
CbrpQic tyrggbm;ytic Jeukenja 
1n chroni; lyn:plxlcytic leukemia a correlamn between semitiviyto fludarabine and TIGAR inducmn mediated by p53 was described. 
The semitiviy offludarabine was variable despite al patients analysed bad wikl type p53 (Lópe7rGuerra et al, 2008). 
Cervb: can:inona 
1n hmnan cervical carchnm cells, RNAi-mediated cilrate synthase illhibitim accelcmted cancer cen prolifi:rati>n and metastasil in in vitro 
assays and in vivo tm:mr xcnognúlm>dels. The l1llin drects ofthil knockdown are related wih sc:vere dei:cts inrespir:atory actiWy and 
marked decreases in A'IP producmn, but increases in glycolyti: metabolism, resulted from deregulation oftbe p53ffiGAR and SC02 
pathways. This phenotyp~ change was complctely reversed by p53 reactivamn suggestiDg 1he impbti>n ofTIGAR in thil malignant 
prolileramn (Lin et al, 2012). 
Globlastona 
Wanka et al (2012) mve sbown in gfublastoma lhat TIGAR is overexpressed and ils expression reduces cen death induced by glucose 
and oxygen restriction. Metabolic analyses reveallhat TIGAR inhbils glycolysis and prom>tes respiration. Furthcr, gencmti>n ofROS is 
reduced whereas lcvels ofreduced GSH are elcvated in TIGAR-expressirlg cells (Wanka et al, 2012). These resuhs agree wilh the 
potcn1ial ofTIGAR as an antil:mmral target dem>nstzated by Peiia-Ri:o et al (20 11 ), wlxl analysed tbe drects ofTIGAR knockdown in 
U87MG and T98G glioblastoma-derived cel lines and conclu:led tbat TIGAR abrogation provides a novel adjunctive therapeuti: strategy 
agail:m glial tum>rs by increasirlg radiati>n-iodlx:ed cel irqJairment, tlnll allowirlg 1he use oflower radi>therapeuti: doses. ~ are 
resirtanl to radiati>n therapy, as wen asto 'INFa induced killing. Radiation-induced 'INFa 1:riggers Nuclear Factor 1CB ~mediated 
radi>resÍS1ml:e. The exiltence of AlM-NFKB axil tbat reptes tbe metaboli: tmdulator TIGAR suggests o irq¡bti>n in tbe 
meclJan6Im tbrougb. whi:h :ioflaimmtDn could affi:ct resistance and adaptamn to radi>mim:ti:s despite concum:Il1 induction of death 
(Sioba et al, 2013). 
Rccently, in a neumhl!stoma SH-SYSY ceRm>del a novedoU'i sonodynami; therapy has been assayed. This noninvasive m>da]J;y :lbr 
cancer treatment is based on the selective activamn of a sonosensitizer agent by acousti: cavitation. The activated sonosensitizer agent 
migbt generate reactive oxygen speces lcadirlg to cancer cen death. This therapy sbowed a significant decrease in SH-SY5Y cen 
prolileramn il vitro in two and three-dimensional neuroblastoma m>dels and thil e1rect was accompanied by a sigoilicant decrease in tbe 
TIGARmRNA expression24lxlurs aft.er sonodynamic treatment (Canaparo etal, 2013). 
Alzbeimer's disease and neurodegenenation 
Some authors reported lhat TIGAR protein levels were decreased in vamus stages of Al2beinWs dilease dementia severity, suggestirlg 
diroirrjqbjng efli:ct of A1M-p53 signalling in counteractirlg cen death illduced by glyoolysE/OXPHO S. The progressive decrease ofTIGAR 
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fiD:tionaDy inactire TP53 ImDOmers and dioEB, but oot fio:t:imally active TP53 tetramers in Al2heimets dmease patiems' brains (Di 
Dom:ni:o et al, 2009; Katsel et al, 2013). Moreover, the reported elevated expression of cmmnmtionaDy a1tered unfi>lded TP53 in 
peq,hcral bk>od ceDs from patients with AJzhcim:r's ~ase (Ube.rti et al, 2008) raiies tbe question ofthe ~ ofprotein stru:tural. 
changes on thc TP53 activity duriog progression of demmt:ia. TP53 actiwtcs TIGAR uoder hw lcvels ofstress. However, iJlhwiog 
extended exposure to stress and tbe ioduction ofthe TP53-mediated apoptotic respome, liGAR expression ti reduced, suggestilg that 
tbe ioduction ofthe apopto& respome may reflect tbe loss ofprotection by tbe TP53-ioducble survival signah (Bensaad et al, 2006). 
There:tbre, liGAR may play a crilical role in the switch ofTP53-ioduced responses to stress anda decrease in ils expression JIBY haw 
oegatM: consequences fur tbe survivalofceDs duriogprogressiJnofdementia {Madanet al, 2012). 
Diabetes and. obesity 
Note Studies perfunned in rats with diabetes JIE!Iitui to evaluate thc potentialrole ofp53 and ils transcr:iptional targets in exetcile-ioduced 
milochorxlrial adaptation in skeletal JWSCle showed a decrease in p53 and liGAR protein levels, indicatiog 1hat exercile traiDing can 
attenuate oxidatiw stress and increase milochondrial DNA cont.ent in skeletal IlllSCle. Agreeing with tbese resuhs, suppressiJn ofp53 and 
liGAR expression coukl play a role in prewnting oxiiative stress in iorulin resmance (Qi et al, 2011 ). 
To be noted 
In tbe sanE direction Denlak et al (2011) reporU:d tbat Slllceptibill;y to etbanol-muced lM:r daJIBge in diffi:rem mt s1mins and tbe 
promJtion of insulin resmance is correlated wilh p53 activation and tbe activation ofTIGAR 
Conclusion: In SUIIIIIm)', since liGAR was discovered in 2006 as a p53 target activated in response to IIDderated stress, several 
fiD:tiom related to ils fhx:tose2,6-bisphospbatase activity haw been described. liGAR has beconE a key protein in tbe regulation of cen 
processes such as apoptosis, autophagy, DNA repair and con1rol of oxidative stress, determioillg 1he mte oftbe cen in response to 
diffurent insuhs. The role ofTIGAR in rmintaining tumJr cel survival is higbligbted by tbe mct that sOnE tmror types haw elevated levels 
ofliGAR expression (Wanka et al, 2012; Won et al, 2012) and 1he inhibition of diffurent 1herapeutic targets is associated wilh a 
decrease ofTIGAR expression. liGAR can belps to support tui!Drigenesis by limitiog ROS and providing precursors fur IDJCleotide 
synlh:sis. Thcse data predict that inbbmn ofTIGAR may carry thempeutic advantage in cancer trea1III:nts as dei!Dmtmted in diffurent 
cancer mxlels (Peña et al, 2011; ~Outschoorn et al, 2011; Cbeuog et al, 2013). 
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